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Hyaluronate (HA)' is an ubiquitous component ofmammalian tissue with many
important structural and functional roles (1). HA also comprises the capsular mate-
rial ofthegroupAStreptococcus (2). Thesepresumably identical polysaccharides have
been ofconsiderable interest as a model for the role ofmicrobialmimicry inautoim-
mune disease (3). Theories have proposed that microbial crossreactions may play
an essential role in the induction and expression of autoantibody (4), possibly via
genomicmechanisms (5). In addition, immunity to streptococcal capsular HA could
conceivably playa role inprotection against streptococcal infections (6, 7), butlittle
evidence has accumulated to support this possibility.
Indeed, HA immunogenicity and antigenicity remain poorly understood. HA has
been thought to be a nonimmunogenic, nonantigenic molecule (8, 9). However, re-
cent studies demonstrated that naturally occurring antibodies to HA are present
in several species (10). Some investigators have demonstrated autoantibodies to HA
that are "broadly crossreactive" (11), and therefore, may be oflow affinity and oflittle
pathogenetic significance.
We have previously shown HA to be immunogenic in rabbits immunized with
formalinized, encapsulated group AStreptococci (12). We now further demonstrate
the immunogenicity ofHAby induction ofantibodies to HAin mice after immuni-
zation with HA bound to liposomes. At least two different antigenic immunodeter-
minants of the HA polysaccharide were identified.
Materials and Methods
Biochemicals
￿
Purified mammalian HA was purchased from MilesLaboratories Inc., (Naper-
ville, IL) Sigma Chemical Co. (St. Louis, MO), andWorthington Biochemical Corp. (Free-
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hold, NJ). Chondroitin 4 sulfate and heparin was obtained from Sigma Chemical Co. Heparan
sulfate was obtained from Miles Laboratories Inc. N-acetylglucosamine, N-acetylgalactosamine,
and glucuronic acid (sodium salt) were obtained from Sigma Chemical Co. Glucuronamide
was obtained from Aldrich Chemical Co. (Milwaukee, WI). Testicular hyaluronidase was ob-
tained from Worthington Biochemical Corp. Biotin and streptavidin were obtained from Sigma
Chemical Co. Synthetic lipids were obtained from Avanti Polar Lipids, Inc. (Birmingham, AL).
Preparation ofStreptococcal Hyaluronate.
￿
Group C streptococcal strain, D181, was grown, har-
vested, and the capsular hyaluronate (fraction IA) released and purified, as previously de-
scribed (12). After partial hydrolysis with testicular hyaluronidase (Worthington Biochemical
Corp.), fraction IAl was recovered by precipitation with alcohol.
Immunization ofRabbits with Encapsulated Streptococci.
￿
Vaccines were prepared by formalde-
hyde treatment of Streptococci harvested in the log phase of growth in an attempt to promote
retention of the capsule, as previously described (12). Rabbits were given a series of intrave-
nous injections with the vaccines, followed by a test bleeding 1 wk after each course ofinjections.
Preparations of Liposomes and the Attachment of Hyaluronate.
￿
80 mg of synthetic phos-
phatidylethanolamine and 20 mg of synthetic phosphatidylcholine were dissolved in chloro-
form and dried on an acid-cleaned glass test tube by rotary evaporation. 1 ml PBS was then
added, and the sample was thoroughly sonicated in a water bath sonicator. The liposomes
were then centrifuged (12,100 g) and washed three times in PBS. The final pellet of liposomes
was resuspended in 2 x volume of PBS and stored at 4°C .
Benzoquinone-derivitized JAI was prepared as previously described (12) . 25 mg IAl in
20 ml PBS was added to 5 ml of 250 mM benzoquinone in 100% ethanol and rotated for
1 h at room temperature in the dark. 100 ml of absolute ethanol with 0.05 M sodium acetate
was added, the mixture brought to 4°C, centrifuged at 17,700 g for 20 min, resuspended
in 100 ml ethanol/acetate, and again centrifuged. The pellet was resuspended in 18 ml of
0 .5 M NaCl and dialyzed against 1 liter of 0.5 M NaCl at 4°C. After this, the material was
dialyzed against 4 liters ofPBS. Equal volumes of the benzoquinone-derivitized IA1 and lipo-
somes were mixed by rotation overnight at 4°C and washed five times by centrifugation in
PBS. The final pellet (2.5 ml) was resuspended in a 2 x volume ofPBS, aliquoted, and stored
at 4°C for use. This material is referred to as IAl-liposomes. Approximately 15 mg of HA
was recovered in the final preparation of IAl-liposomes, as approximated by the measure-
ment ofuronic acid in the sample (13). For immunologic experiments, the amount of uronic
acid (gg/ml) in a given volume of IAl-liposomes was measured and used for quantitation
of the amount of HA in the sample.
Immunization ofMice with HA.
￿
Four BALB/c/SJL x F, mice were immunized with IAl-
liposomes. Preimmune sera were taken intraorbitally. 100 gl of IAl-liposomes in PBS (con-
taining 1 mg/ml of HA determined, as described in the preceding section) were injected in-
traperitoneally. 2 wk later, mice were bled and immunized. This was repeated a third and
final time 2 wk later. Another group of five mice initially received 100 41 of a solution con-
taining 50 wl IA1 in PBS (2 mg/ml) and 50 wl of CFA, which was mixed to form an emulsion.
Subsequent immunizations used IFA. The same immunization protocol as described above
for IAl-liposomes was used.
Production ofHybridomas and mAbs.
￿
Standard methods for the production of hybridomas
were used (14) . Two fusions were performed using the pooled spleen cells from each group
of mice. Briefly, spleens were dissected, minced, and the cells from the spleens of each group
of mice were separately pooled for fusion with NS-1 myeloma cells. After fusion, cells were
plated in DME media containing 10% CPSR-3 supplement (Sigma Chemical Co.), hypox-
anthine, aminopterin, and thymidine (HAT) and maintained in this medium throughout
subcloning. 14 d after fusion, the hybridoma supernatants were removed and tested for anti-
body activity using the ELISA described below. ELISA-positive clones were replated for sub-
cloning, and were retested at confluence. A total of three subclonings were performed, at
which time the subclones were presumed to be monoclonals. Subsequent limiting dilution
experiments confirmed that these were indeed single clones. The clones were grown to 2-liter
volumes in DME plus CPSR-3 and the supernatant fluid concentrated by precipitation with
18% sodium sulfate. The precipitate was resuspended in 20 ml 0.01 M sodium phosphate,
pH 7 .0, to which 20 ml of a 30% PEG in sodium phosphate buffer was added. After centrifu-FILLIT ET AL.
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gation, the precipitate was resuspended in sodium phosphate buffer and applied to a hydrox-
ylapatite (Calbiochem-Behring Corp., La Jolla, CA) column equilibrated in sodium phos-
phate buffer. A linear gradient between 10 and 300 mM of sodium phosphate was applied,
and the fractions were assayed for reactivity by ELISA. The reactive fractions were collected
and pooled.
ELISA.
￿
This assay was performed as we previously described (12) using streptavidin and
biotin-labeled IA1 (IAl-B). ELISAplates (Immunoplate II ; Nunc, Roskilde, Denmark) were
coated with streptavidin at 10 Rg/ml in 0.1 M carbonate buffer, pH 9.1, at room temperature
for 1 h and then overnight at 4°C . After washing, IAl-B (5 ug/ml) in 0.1 M PBS with 0.5%
Brij (PBSB) was added for 1 h. After washing, rabbit sera or mAbs were added at varying
dilutions in PBSB for 1 h. For competitive immunoinhibition experiments, diluted sera and
inhibitor (in PBSB) were rotated for 1 h at room temperature, and overnight at 4°C, cen-
trifuged in a microfuge (12,100 g), and the supernatant was used in the ELISA. Finally, after
an incubation with alkaline phosphatase-conjugated goat anti-rabbit IgG (1 :1,000) or
anti-mouse IgG antisera (1 :350) (Sigma Chemical Co.) in PBSB for 1 h, the plates were washed,
and developer was added. The plates were incubated at 37°C and read at 1 h at 405 nm
in an automated ELISA reader (Physica, Long Island City, NY).
Alterations of Hyaluronatefor Immunochemical Studies.
￿
Mammalian and testicular HA were
treated with testicular hyaluronidase as described previously (12). HA was treated with ascorbic
acid according to modifications of previous methods (15) . 10 mg IA was dissolved in 1 ml
PBS. To this solution was added 5 mg of ascorbic acid and 5 ul of 1 M copper sulfate. The
mixture was intermittently rotated manually for 3 h at room temperature. An additional
5 mg of ascorbic acid and 5 ul of 1 M copper sulfate was added, rotated, and the mixture
incubated for 3 d at 4°C. Finally, HA was also treated by ultrasonication according to modifica-
tions of previous methods (16). 2 ml of a 10 mg/ml solution of IA in PBSA was placed in
a 2.5-cm-thick pyrex tube. The tube was placed in an ice bath. A probe sonicater (Heat Systems-
Ultrasonics, Inc., Farmingdale, NY; Ultrasonic processor W-380) was used with the output
control at "4". The material was intermittently sonicated with power on for 1 s and power
off for 3 s (to prevent heating) for 4 h.
Chromatography of Treated HA.
￿
Hyaluronidase-treated HA, sonicated HA, and ascorbate-
treated HA in PBSA were chromatographed on Sephacryl S-200, using a 100 x 1 .5-cm column
at a flow rate of 10.5 ml/h, with PBSA as the running buffer. 2-ml fractions were collected
and tested for the presence of uronic acid (13). Peaks containing HA were pooled, dialyzed
against distilled water, lyophilized, and stored at 4°C for use in immunologic assays.
Results
Immunogenicity ofHA in Mice.
￿
To demonstrate that the IAl-liposomes contained
immunoreactive HA antigen, immune rabbit sera were used in competitive immunoin-
hibition experiments (Fig. 1). IA1-liposomes effectively inhibited immune rabbit sera
reactivity to 1A1, while untreated liposomes had little effect . Liposomes could not
be reacted at concentrations >100 gg/ml, since thick emulsions were formed at these
concentrations. The inhibitorycapacity in immune rabbit sera ofIA1-liposomes was
intermediate between intact HA (IA) and hyaluronidase-digested HA (IM). These
results confirmed that IA1-liposomes contained immunoreactive HA antigen.
Four mice were immunized with IA1-liposomes, and five mice were immunized
with IAl in Freund's adjuvant (IAl-FA). Serial bleedings were taken from each im-
munized mouse. While the mice immunized with IAl-liposomes developed serum
antibody to IAl by ELISA, the mice immunized with 1A1-FA did not develop mea-
surable antibody to IA1 (Fig. 2).
Pooled spleens from three mice immunized with IAl-liposomes were used for
production ofhybridomas. Supernatants from culture wells of microtiterplates were
tested for production of antibody to IA1 by ELISA. Four hybridomas were identified97 4
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that produced antibody to IAl. Hybridomas producing antibody to IA1 were sub-
cloned by limiting dilution . Of the initial four clones, two hybridomas ceased anti-
body production, and two were stable after three subclonings (10G6 and 5F11).
Immunochemical Characterization ofMouse m4bs to HA.
￿
Monoclonals 10G6 and 5F11
were characterized immunologically. Both hybridomas produced IgG antibody (data
not shown) and recognized human and streptococcal HA by competitive ELISA
inhibition (Fig. 3).
The effects of various treatments on HA antigenicity were explored (Fig. 3). As
we have previously demonstrated in immune rabbit sera, testicular hyaluronidase
digestion enhanced the antigenicity of streptococcal and human HA for 10G6 .
Hyaluronidase treatmentalso enhanced theantigenicity of streptococcal HA for5F11 .
Thus, testicular hyaluronidase treatment exposes a specific terminal HA antigenic
site on IA recognized by both mAbs. Ascorbic acid treatment markedly reduced
IA antigenicity for 5F11, but had little effect on IA antigenic recognition by 10G6,
suggesting that the antigenic site on IA recognized by 5F11, but not 10G6, is de-
stroyed by oxidation. Sonication of intact human and streptococcal HA had little
effect on the reactivity ofthe mAbs. As determined by Sephacryl S-200 chromatog-
raphy(data notshown), all threetreatments had similareffects in reducing the chain
length of the IA to an approximate molecular weight of 1.5 x 104 kD. These data
FIGURE 2.
￿
ELISA titers of antibody to IAl in sera from mice
immunized with IA1 either conjugated to liposomes (IA1-
liposomes), or in Freund's adjuvant (IAI/FA). Results(mean +/-
SE) areexpressed as the observed OD, 405 nm) in mictotiter
wellscontaining antigen (IAI) minus OD in wellswithoutan-
tigen as background control.A
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Competitive inhibition ELISA
studies of mAbs IOG6 (A) and 51711 (B)
usingvarious hyaluronate preparations as
inhibitors. Results areexpressed as in Fig.
1. son-IA, sonicatedIA; asc-IA, ascorbate-
treatedIA;HuHya, intact humanhyaluro-
nate; HA-aseHuHya, hyaluronidase-treated
HuHya; son-HuHya, sonicated HuHya.
demonstrate that HA immunogenicity is not simply a function of chain length, but
rather, is dependent on immunospecific epitopes that are demonstrable by specific
treatments and differentially recognized by the two mAbs.
Differences in the exact HA epitope that the mAbs recognized were also found
when the mode of presentation of HA was explored (Fig. 4). IOG6 recognized an
immunodeterminant that was most effectively presented when IM was bound to
liposomes, rather than free in solution. In contrast, 51711 reacted most effectively
with free IAl. Essentially no reactivity was noted with unconjugated liposomes used
as control. These data clearlyindicate that the two anti-HAmAbs recognize different
sites on HA that are differentially exposed when free in solution or on liposomes.
The immunochemical specificity of the epitope recognized by the mAbs was ex-
plored by usingspecific competitiveimmunoinhibitors. lOG6 waseffectively inhibited
by as little as 0.5 M glucuronic acid. However, none of the monosaccharides tested
inihibited reactivity to IM by 51711 (Fig. 5). IOG6 did not crossreact with other
glycosaminoglycans tested (Fig. 6). However, 51711 did crossreact with heparan sul-
fate, although at a considerably lower affinity than IAl. In addition, while 10G6
did not crossreact with polyanionic phosphorylated molecules (Fig. 7), including
DNA, 51711 showed crossreactivitywith phosphorylcholine, again at a considerably
lower affinity than IAl.976
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Competitative inhibition ELISA
studiesofmAbs 10G6 (A)and 5F11 (B) using
various hyaluronate inhibitors.
These data suggested that electrostatic forces might play a role in the immuno-
dominant site recognized by 5F11. To test this hypothesis, titrations of the mAbs
reactivity to IA1 in the presence ofvaryingdilutions of NaCl were performed (Fig.
8). Increasing concentrations ofNaClhad no effect on the reactivity of 10G6 to IA1.
However, the addition of 0.5 M NaCl reduced the reactivity of5F11 for HA, indi-
cating that electrostatic charge does playa roleinthe immunodominant site of5F11.
Discussion
The immunogenicity of HA in rabbits has been previously demonstrated using
encapsulated groupA streptococcal cells as immunogen(12). Tofurtherdemonstrate
that HA is immunogenic, we attempted to induce an immune response to HA in
another animal species using a different HA immunogen. We speculated that HA
on the streptococcal cell may exist as a polymer extending radially outward from
the membrane, and that this configuration might be important to the immunoge-
nicity ofencapsulated streptococcal cells. We hypothesized that HA linked to the
exterior ofliposomesmight present terminal HA immunodeterminants in amanner
similar to streptococcal cells. The presence of HA on the exterior of the liposomes
was confirmed by biochemical data showing uronic acid in IAI-liposomes, and the
demonstration that immune rabbit sera, known to contain antibodies to HA ter-0
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FIGURE 5.
￿
Competitive inhibition ELISA
studies of mAbs 1OG6 (A) and 51`11 (B)
using various monosaccharides as inhibi-
tors.
minal immunodeterminants (12), effectively reacted with IM-liposomes. Serial
bleedingsof mice immunized with IAl-liposomesdemonstrated a significant increase
in antibody titerto HA, whilemice immunizedwith free IA1 in an emulsion (Freund's
adjuvant) did not. These data confirm the immunogenicity ofHA, and indicate that
the mode ofpresentation of HA is important in its immunogenicity. Thesignificance
of radially arrayed, multiple terminal immunodeterminants in the immunogenicity
of vaccines has been previously discussed in regard to the streptococcal group poly-
saccharides (17).
Immune rabbit sera and mAb IOG6 appear to recognize a similar terminal HA
immunodeterminant specifically exposed by mammalian hyaluronidase digestion,
and containing glucuronic acid in the immunodominant site. Neither sonication
nor ascorbic acid treatment of HA had any significant effect on its reactivity with
10G6, indicating that the terminal site recognized by 10G6 is uniquely exposed by
testicular hyaluronidase treatment. Furthermore, IOG6 showed no crossreactions with
any glycosaminoglycans or phosphorylated compounds tested, and the addition of
NaCl had no effect on 10G6 immunoreactivity. These data indicate that electrostatic
forces do not play a major role in the immunodominant site recognized by 10G6.
While immune rabbit sera recognized free IA1 more effectively than Ial-liposomes,
mAb 1OG6 recognized IAl-liposomes far more effectively than free IAl. The expla-
nation for these more subtle immunologic differences between immune rabbit sera
and mAb 1OG6 require further investigation. In summary, IOG6 mAb is im-978
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munospecific for a unique terminal HA epitope, which is also recognized by im-
mune rabbit sera.
The immunodominant site ofHA recognized bymAb 5F11 was investigated. mAb
5F11 also recognized an immunodeterminant on IAexposed byhyaluronidase diges-
tion. However, in contrast to immune rabbit sera and mAb 10G6, mAb 5F11 was
not inhibited by glucuronic acid, indicating that this monosaccharide alone does
represent the immunodominant site recognized by 5F11. The immunodeterminant
recognized by 5F11 could bethe complete terminal disaccharide unit, hyalobiuronic
acid, or a larger oligosaccharide unit. In addition, again in contrast to 10G6, 5F11
was more effectively inhibited by free IA1 than IA1-liposomes. These data suggest
that 5F11 most effectively recognizes a monovalent, rather than a polyvalent, ter-
minal immunodeterminant, or that the immunodominant site recognized by 5F11
mayberelatively hidden in the IAl-liposomes. The factthatascorbic acid specifically
destroyed the immunodominant site recognized by 5F11 suggests that the im-
munodominant site is susceptible to oxidation. Previous studies have explored the
biochemistry ofoxidativereactionsofHA(15, 18, 19). Configuration may be impor-
tant in the susceptibilityofHA carboxylategroups to oxidation (20), and thus, con-
formational factors may be important in the antigenic sites of HA recognized by0
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FIGURE 7. Competitive inhibition ELISA
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tors.
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51`11. However, the exact biochemistry of ascorbate-induced oxidative reactions of
HA is not known.
Antibody crossreactions in which electrostatic forces play a role have been previ-
ously demonstrated (4, 21). It has been suggested (22) that electrostatic forces may
also play a role in crossreactions between HA and DNA. Our mAbs did not cross-
react with DNA, indicating the possibility ofa third antigenic site on HA, in addi-
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tion to the two we have demonstrated. Although electrostatic forces appear to con-
tribute to theimmunodominant site recognized by 5F11, electrostatic forces are only
partially responsible for the immunospecificity of 5F11, since only specific
glycosaminoglycans and phosphorylated compoundswere effective as immunoinhi-
bitors. As discussed above, the configuration or conformation ofcharged groups may
be important in the immunodominant site recognized by 5F11.
It is particularly interesting to note that 5F11 recognizes a crossreactive site on
HA and heparan sulfate (HS) in which electrostatic forces play an important role.
Anionic sites on HS are critical to the maintenance of the normal charge-barrier
function ofthe vascular premeability barrier(23). Thus, crossreactions between HA
and HS anionic sites could be involved in the pathogenesis of autoimmune vascular
disease. Such crossreactions could be initiated by mechanisms related to microbial
mimicry (3). Antibodies to HS have been demonstrated to cause proteinuria in an-
imal models (24) and to be present in the glomeruli of animals and patients with
glomerulonephritis (11). We also demonstrated the presence of crossreactions be-
tween HA and HS in human sera from patients with glomerulonephritis (25).
Quantitative differences in the immunoreactivity of preparations of human HA
and streptococcal HA were noted in several of our experiments. Based on our cur-
rent knowledge of the biochemistry of HA, it seems unlikely that this represents
true antigenic variationbetween these HA preparations. However, possible immuno-
logic differences based on sequence variations cannot be completely ruled out. Differ-
ences in the chainlength of the intact HA molecule obtained by different extraction
methods, or naturally occuring differences in the chain length of HA produced by
Streptococci and mammalian cells, more likely account for variations in antigenicity
of different HA preparations. Forexample, themolaramountsof terminal antigenic
determinants in agiven preparation of HA would depend on the mean chainlength
ofthe HA chains in thepreparation. However, it is also clearthat chain length alone
does not determine the antigenicity of a given HA preparation. For example, al-
though sonication, ascorbate oxidation, and hyaluronidase treatment reduced the
chain length of HA to a similar degree, hyaluronidase enhanced the antigenicity
of intact HA, sonication had no effect on intact HA antigenicity, and ascorbate oxi-
dation destroyed the site on intact HA recognized by 5F11.
The current investigations not only confirm the immunogenicity of HA, but fur-
ther demonstrate the presence of at least two different antigenic sites on HA. mAbs
represent an important method for immunological studies of hyaluronic acid. The
occurrence of HA in normal serum (1), and the ubiquity of the molecule in mam-
malian tissue, probably absorbs most naturally produced antibody and prevents its
detection. Hybridomatechnology circumvents this problem, andallows the full array
of immune responses to HA immunodeterminants to be detected and studied.
Summary
Hyaluronate (HA) was previously demonstrated to be immunogenic in rabbits.
The immunogenicity ofHA in mice was studied. Hyaluronidase-digested streptococcal
HA (IA1) covalently linked to liposomes (IAl-liposomes) were produced for immu-
nization . Mice immunized with IAl-liposomes developed measurable serum anti-
bodies to IAl, while mice immunized with IA1 in Freund's adjuvant did not. mAbs
produced by two stable hybridomas (IOG6 and 5F11) from mice immunized withFILLIT ET AL.
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IAl-liposomes produced IgG antibody reactive with HA in ELISA. 10G6 had a much
higher avidity for liposome-bound IAl than free IAl, while 5F11 did not, suggesting
that the mode of presentation of IAl is important in HA immunogenicity and anti-
genicity. Both mAbs recognized terminal HA immunodeterminants exposed by
hyaluronidase treatment. Sonication had no effect on HA reactivity for either mAb.
However, ascorbic acid treatment significantly reduced the antigenicity of HA for
mAb 5F11, but not 1OG6. Only IOG6 was inhibited by glucuronic acid. Electrostatic
forces appear to play a role in the binding site of5F11, but not 10G6. 5F11 crossreacts
with heparan sulfate and phosphorylcholine, while 1OG6 did not crossreact with any
glycosaminoglycans or phosphorylated compounds tested.
These results confirm that HA is immunogenic. They suggest that the mode of
presentation of HA is important for the induction of the immune response, and in
HA antigenicity. At least two different antigenic sites on HA were demonstrated.
1OG6 recognizes a terminal HA antigenic site expressed on IAl-liposomes that con-
tains glucuronic acid in its immunodominant site. 5F11 recognizes an HA antigenic
site in which electrostatic forces appear to play a role, is sensitive to ascorbic acid
treatment, and is crossreactive with heparan sulfate. The use of mAbs should facili-
tate immunologic studies of HA.
Receivedforpublication 19 October 1987 and in revisedform 16 May 1988.
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